{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:44:47Z","timestamp":1793814287787,"version":"4.6.1"},"reference-count":107,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which multiple organs are damaged by the immune system. Although standard treatment options such as hydroxychloroquine (HCQ), glucocorticoids (GCs), and other immunosuppressive or immune-modulating agents can help to manage symptoms, they do not offer a cure. Hence, there is an urgent need for the development of novel drugs and therapies. In recent decades, cell therapies have been used for the treatment of SLE with encouraging results. Hematopoietic stem cell transplantation, mesenchymal stem cells, regulatory T (Treg) cell, natural killer cells, and chimeric antigen receptor T (CAR T) cells are advanced cell therapies which have been developed and evaluated in clinical trials in humans. In clinical application, each of these approaches has shown advantages and disadvantages. In addition, further studies are necessary to conclusively establish the safety and efficacy of these therapies. This review provides a summary of recent clinical trials investigating cell therapies for SLE treatment, along with a discussion on the potential of other cell-based therapies. The factors influencing the selection of common cell therapies for individual patients are also highlighted.<\/jats:p>","DOI":"10.1093\/stcltm\/szae044","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T11:56:47Z","timestamp":1719403007000},"page":"859-872","source":"Crossref","is-referenced-by-count":25,"title":["Current cell therapies for systemic lupus erythematosus"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-3342","authenticated-orcid":false,"given":"Lan T M","family":"Dao","sequence":"first","affiliation":[{"name":"Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System , Hanoi 100000 , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu Thuy","family":"Vu","sequence":"additional","affiliation":[{"name":"Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System , Hanoi 100000 , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quyen Thi","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System , Hanoi 100000 , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van T","family":"Hoang","sequence":"additional","affiliation":[{"name":"Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System , Hanoi 100000 , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-0161","authenticated-orcid":false,"given":"Thanh Liem","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vinmec Research Institute of Stem Cell and Gene Technology, Vinmec Healthcare System , Hanoi 100000 , Vietnam"},{"name":"Vinmec International Hospital, Center of Regenerative Medicine and Cell Therapy, Vinmec Healthcare System , Hanoi 100000 , Vietnam"},{"name":"Vin University, College of Health Sciences , Hanoi 100000 , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"2024091018592818700_CIT0001","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"2024091018592818700_CIT0002","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2024091018592818700_CIT0003","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1177\/0961203318776093","article-title":"Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients","volume":"27","author":"Leuchten","year":"2018","journal-title":"Lupus"},{"issue":"10","key":"2024091018592818700_CIT0004","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/cells8101180","article-title":"Update on the genetics of systemic lupus erythematosus: genome-wide association studies and beyond","volume":"8","author":"Kwon","year":"2019","journal-title":"Cells"},{"issue":"5","key":"2024091018592818700_CIT0005","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/BOR.0000000000000318","article-title":"Environmental exposures and the development of systemic lupus erythematosus","volume":"28","author":"Barbhaiya","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"2024091018592818700_CIT0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/OARRR.S166303","article-title":"Management of refractory lupus nephritis: challenges and solutions","volume":"11","author":"Yo","year":"2019","journal-title":"Open Access Rheumatol"},{"issue":"7","key":"2024091018592818700_CIT0007","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/s41409-022-01702-w","article-title":"Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"57","author":"Alexander","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2024091018592818700_CIT0008","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"2024091018592818700_CIT0009","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","article-title":"The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults","volume":"57","author":"Gordon","year":"2018","journal-title":"Rheumatology"},{"issue":"11","key":"2024091018592818700_CIT0010","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2018-213512","article-title":"First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)\u2013Pan-American League of Associations of Rheumatology (PANLAR)","volume":"77","author":"Pons-Estel","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2024091018592818700_CIT0011","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2478\/rir-2020-0009","article-title":"2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus","volume":"1","author":"Li","year":"2020","journal-title":"Rheumatol Immunol Res"},{"issue":"Suppl 1","key":"2024091018592818700_CIT0012","doi-asserted-by":"crossref","first-page":"i22","DOI":"10.1093\/rheumatology\/keac678","article-title":"Dilemma of immunosuppression and infection risk in systemic lupus erythematosus","volume":"62","author":"He","year":"2023","journal-title":"Rheumatology"},{"key":"2024091018592818700_CIT0013","doi-asserted-by":"crossref","first-page":"622225","DOI":"10.3389\/fmed.2021.622225","article-title":"The use of glucocorticoids in lupus nephritis: new pathways for an old drug","volume":"8","author":"Mej\u00eda-Vilet","year":"2021","journal-title":"Front Med"},{"key":"2024091018592818700_CIT0014","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","article-title":"B cell alterations during BAFF inhibition with belimumab in SLE","volume":"40","author":"Ramsk\u00f6ld","year":"2019","journal-title":"EBioMedicine"},{"issue":"6","key":"2024091018592818700_CIT0015","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/096120339700600613","article-title":"Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration","volume":"6","author":"Marmont","year":"1997","journal-title":"Lupus"},{"issue":"4","key":"2024091018592818700_CIT0016","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood-2005-07-2800","article-title":"Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network","volume":"107","author":"de Kleer","year":"2006","journal-title":"Blood"},{"issue":"4 Suppl 98","key":"2024091018592818700_CIT0017","first-page":"53","article-title":"Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases","volume":"34","author":"Alexander","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"2024091018592818700_CIT0018","first-page":"107","article-title":"Resetting the immune response after autologous hematopoietic stem cell transplantation for autoimmune diseases","volume":"64","author":"Arruda","year":"2016","journal-title":"Curr Res Transl Med"},{"key":"2024091018592818700_CIT0019","doi-asserted-by":"crossref","volume-title":"Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases","author":"Burt","DOI":"10.1201\/9781315151366"},{"issue":"1","key":"2024091018592818700_CIT0020","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13223-019-0373-y","article-title":"Haemopoietic stem cell transplantation in systemic lupus erythematosus: a systematic review","volume":"15","author":"de Silva","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"5","key":"2024091018592818700_CIT0021","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1191\/0961203304lu1027oa","article-title":"Autologous stem cell transplantation for systemic lupus erythematosus","volume":"13","author":"Jayne","year":"2004","journal-title":"Lupus"},{"issue":"5","key":"2024091018592818700_CIT0022","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2215\/CJN.10570918","article-title":"Autologous hematopoietic stem cell transplantation for refractory lupus nephritis","volume":"14","author":"Huang","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4 Pt 2","key":"2024091018592818700_CIT0023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/pr.2011.57","article-title":"Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases","volume":"71","author":"Daikeler","year":"2012","journal-title":"Pediatr Res"},{"issue":"6","key":"2024091018592818700_CIT0024","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1182\/blood-2011-02-336156","article-title":"Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party","volume":"118","author":"Daikeler","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2024091018592818700_CIT0025","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bmt.2011.185","article-title":"Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation","volume":"47","author":"Snowden","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024091018592818700_CIT0026","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13287-022-02782-7","article-title":"Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases","volume":"13","author":"Jasim","year":"2022","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"2024091018592818700_CIT0027","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/stem.68","article-title":"Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans","volume":"27","author":"Sun","year":"2009","journal-title":"Stem Cells"},{"issue":"8","key":"2024091018592818700_CIT0028","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/ard.2009.123463","article-title":"Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study","volume":"69","author":"Liang","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2024091018592818700_CIT0029","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/art.27548","article-title":"Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus","volume":"62","author":"Sun","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024091018592818700_CIT0030","doi-asserted-by":"crossref","first-page":"728190","DOI":"10.3389\/fimmu.2021.728190","article-title":"Mesenchymal stem cell therapy: hope for patients with systemic lupus erythematosus","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2024091018592818700_CIT0031","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1038\/s41467-019-10491-8","article-title":"Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients","volume":"10","author":"Yuan","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"2024091018592818700_CIT0032","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.25011\/cim.v46i1.39561","article-title":"Efficacy of mesenchymal stem cell therapy on lupus nephritis and renal function in systemic lupus erythematosus: a meta-analysis","volume":"46","author":"Xia","year":"2023","journal-title":"Clin Invest Med"},{"issue":"3","key":"2024091018592818700_CIT0033","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/0961203309348983","article-title":"Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients","volume":"19","author":"Carrion","year":"2010","journal-title":"Lupus"},{"issue":"1","key":"2024091018592818700_CIT0034","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13287-018-0898-x","article-title":"Genetic contribution to mesenchymal stem cell dysfunction in systemic lupus erythematosus","volume":"9","author":"Zhu","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"2024091018592818700_CIT0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fcell.2019.00285","article-title":"Mesenchymal stem cells: allogeneic MSC may be immunosuppressive but autologous MSC are dysfunctional in lupus patients","volume":"7","author":"Cheng","year":"2019","journal-title":"Front Cell Dev Biol"},{"issue":"23","key":"2024091018592818700_CIT0036","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1161\/CIRCULATIONAHA.110.955971","article-title":"Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair","volume":"122","author":"Huang","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"2024091018592818700_CIT0037","doi-asserted-by":"crossref","first-page":"a015560","DOI":"10.1101\/cshperspect.a015560","article-title":"Mesenchymal stromal cells in transplantation rejection and tolerance","volume":"3","author":"English","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"2024091018592818700_CIT0038","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1681\/ASN.2019050545","article-title":"Additive therapeutic effects of mesenchymal stem cells and IL-37 for systemic lupus erythematosus","volume":"31","author":"Xu","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2024091018592818700_CIT0039","first-page":"84","article-title":"Bio-inspired adhesive porous particles with human MSCs encapsulation for systemic lupus erythematosus treatment","volume":"6","author":"Nie","year":"2021","journal-title":"Bioact Mater"},{"key":"2024091018592818700_CIT0040","doi-asserted-by":"crossref","first-page":"101454","DOI":"10.1016\/j.nantod.2022.101454","article-title":"ECM-inspired peptide dendrimer microgels with human MSCs encapsulation for systemic lupus erythematosus treatment","volume":"43","author":"Zhu","year":"2022","journal-title":"Nano Today"},{"issue":"12","key":"2024091018592818700_CIT0041","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1038\/s41375-020-01041-z","article-title":"Extracellular microvesicles\/exosomes: discovery, disbelief, acceptance, and the future","volume":"34","author":"Ratajczak","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2024091018592818700_CIT0042","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.3390\/ijms25042444","article-title":"Potential therapeutic application and mechanism of action of stem cell-derived extracellular vesicles (EVs) in systemic lupus erythematosus (SLE)","volume":"25","author":"Rajeev Kumar","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2024091018592818700_CIT0043","doi-asserted-by":"crossref","first-page":"13101","DOI":"10.1038\/s41598-022-17331-8","article-title":"Human umbilical cord mesenchymal stem cells derived extracellular vesicles regulate acquired immune response of lupus mouse in vitro","volume":"12","author":"Xie","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"2024091018592818700_CIT0044","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1080\/08820139.2022.2055478","article-title":"Mesenchymal stem cells-derived exosomes ameliorate lupus by inducing M2 macrophage polarization and regulatory T cell expansion in MRL\/lpr mice","volume":"51","author":"Sun","year":"2022","journal-title":"Immunol Invest"},{"issue":"1","key":"2024091018592818700_CIT0045","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s13287-022-03174-7","article-title":"Mesenchymal stem cell-derived exosome-educated macrophages alleviate systemic lupus erythematosus by promoting efferocytosis and recruitment of IL-17+ regulatory T cell","volume":"13","author":"Zhang","year":"2022","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"2024091018592818700_CIT0046","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"2024091018592818700_CIT0047","doi-asserted-by":"crossref","first-page":"698607","DOI":"10.3389\/fonc.2021.698607","article-title":"Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a systematic review and meta-analysis","volume":"11","author":"Meng","year":"2021","journal-title":"Front Oncol"},{"key":"2024091018592818700_CIT0048","doi-asserted-by":"crossref","first-page":"934343","DOI":"10.3389\/fimmu.2022.934343","article-title":"Regulatory CAR-T cells in autoimmune diseases: progress and current challenges","volume":"13","author":"Riet","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"2024091018592818700_CIT0049","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2024091018592818700_CIT0050","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2567.2005.02306.x","article-title":"Inverse correlation between CD4+ regulatory T-cell population and autoantibody levels in paediatric patients with systemic lupus erythematosus","volume":"117","author":"Lee","year":"2006","journal-title":"Immunology"},{"issue":"5","key":"2024091018592818700_CIT0051","doi-asserted-by":"crossref","first-page":"93","DOI":"10.21037\/atm.2019.01.38","article-title":"Significant association of CD4+CD25+Foxp3+ regulatory T cells with clinical findings in patients with systemic lupus erythematosus","volume":"7","author":"Yang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"4","key":"2024091018592818700_CIT0052","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/09612033221083269","article-title":"The relation of CD4+CD25+Foxp3+ regulatory T cells concentration with disease activity and damage index in systemic lupus erythematosus","volume":"31","author":"Kamal","year":"2022","journal-title":"Lupus"},{"key":"2024091018592818700_CIT0053","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fimmu.2019.00159","article-title":"The regulatory T cell in active systemic lupus erythematosus patients: a systemic review and meta-analysis","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"2024091018592818700_CIT0054","doi-asserted-by":"crossref","first-page":"1759720X","DOI":"10.1177\/1759720X20953336","article-title":"Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis","volume":"12","author":"Peng","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"2024091018592818700_CIT0055","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/S2665-9913(19)30018-9","article-title":"Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial","volume":"1","author":"Humrich","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"2024091018592818700_CIT0056","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/art.40737","article-title":"Adoptive Treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall\u2019Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2024091018592818700_CIT0057","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2024091018592818700_CIT0058","doi-asserted-by":"crossref","first-page":"100645","DOI":"10.1016\/j.blre.2019.100645","article-title":"Autoimmunity as a target for chimeric immune receptor therapy: a new vision to therapeutic potential","volume":"41","author":"Haddadi","year":"2020","journal-title":"Blood Rev"},{"key":"2024091018592818700_CIT0059","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fimmu.2014.00555","article-title":"Regulatory T cell-derived exosomes: possible therapeutic and diagnostic tools in transplantation","volume":"5","author":"Agarwal","year":"2014","journal-title":"Front Immunol"},{"issue":"6","key":"2024091018592818700_CIT0060","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/art.24556","article-title":"Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus","volume":"60","author":"Park","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024091018592818700_CIT0061","doi-asserted-by":"crossref","first-page":"645478","DOI":"10.3389\/fimmu.2021.645478","article-title":"Restoration of NK cell cytotoxic function with elotuzumab and daratumumab promotes elimination of circulating plasma cells in patients with SLE","volume":"12","author":"Humbel","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2024091018592818700_CIT0062","doi-asserted-by":"crossref","first-page":"100003","DOI":"10.1016\/j.xcrm.2020.100003","article-title":"Therapeutic targeting of follicular T cells with chimeric antigen receptor-expressing natural killer cells","volume":"1","author":"Reighard","year":"2020","journal-title":"Cell Rep Med"},{"issue":"4","key":"2024091018592818700_CIT0063","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B cells: origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"2024091018592818700_CIT0064","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.immuni.2009.11.009","article-title":"CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients","volume":"32","author":"Blair","year":"2010","journal-title":"Immunity"},{"issue":"9","key":"2024091018592818700_CIT0065","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.4049\/jimmunol.0902385","article-title":"Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity","volume":"184","author":"Watanabe","year":"2010","journal-title":"J Immunol"},{"issue":"6","key":"2024091018592818700_CIT0066","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.4049\/jimmunol.0803052","article-title":"Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL\/lpr mice","volume":"182","author":"Blair","year":"2009","journal-title":"J Immunol"},{"issue":"8","key":"2024091018592818700_CIT0067","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2024091018592818700_CIT0068","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jid.2018.08.023","article-title":"Expansion of myeloid-derived suppressor cells in the peripheral blood and lesional skin of cutaneous lupus patients","volume":"139","author":"Florez-Pollack","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"331","key":"2024091018592818700_CIT0069","doi-asserted-by":"crossref","first-page":"331ra40","DOI":"10.1126\/scitranslmed.aae0482","article-title":"Arginase-1-dependent promotion of TH17 differentiation and disease progression by MDSCs in systemic lupus erythematosus","volume":"8","author":"Wu","year":"2016","journal-title":"Sci Transl Med"},{"key":"2024091018592818700_CIT0070","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3389\/fimmu.2019.01202","article-title":"Increased CD14+HLA-DR\u2212\/low myeloid-derived suppressor cells correlate with disease severity in systemic lupus erythematosus patients in an iNOS-dependent manner","volume":"10","author":"Wang","year":"2019","journal-title":"Front Immunol"},{"key":"2024091018592818700_CIT0071","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.expneurol.2016.09.012","article-title":"Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis","volume":"286","author":"Casacuberta-Serra","year":"2016","journal-title":"Exp Neurol"},{"issue":"6","key":"2024091018592818700_CIT0072","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1189\/jlb.3A0415-158R","article-title":"Immunosuppressive CD11b+Ly6Chi monocytes in pristane-induced lupus mouse model","volume":"99","author":"Ma","year":"2016","journal-title":"J Leukoc Biol"},{"issue":"11","key":"2024091018592818700_CIT0073","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/art.39767","article-title":"Myeloid-derived suppressor cells induce the expansion of regulatory B cells and ameliorate autoimmunity in the sanroque mouse model of systemic lupus erythematosus","volume":"68","author":"Park","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024091018592818700_CIT0074","doi-asserted-by":"crossref","first-page":"104276","DOI":"10.1016\/j.cellimm.2020.104276","article-title":"Extracellular vesicles released by myeloid-derived suppressor cells from pregnant women modulate adaptive immune responses","volume":"361","author":"Dietz","year":"2021","journal-title":"Cell Immunol"},{"issue":"12","key":"2024091018592818700_CIT0075","doi-asserted-by":"crossref","first-page":"2250345","DOI":"10.1002\/eji.202250345","article-title":"Myeloid-derived suppressor cells in the therapy of autoimmune diseases","volume":"53","author":"Beki\u0107","year":"2023","journal-title":"Eur J Immunol"},{"issue":"10","key":"2024091018592818700_CIT0076","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.humimm.2021.06.008","article-title":"Myeloid-derived suppressor cells: important communicators in systemic lupus erythematosus pathogenesis and its potential therapeutic significance","volume":"82","author":"Asgarzade","year":"2021","journal-title":"Hum Immunol"},{"issue":"2","key":"2024091018592818700_CIT0077","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clim.2013.04.017","article-title":"Tolerogenic dendritic cells as a therapy for treating lupus","volume":"148","author":"Llanos","year":"2013","journal-title":"Clin Immunol"},{"issue":"4","key":"2024091018592818700_CIT0078","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/imm.13119","article-title":"Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice","volume":"158","author":"Funes","year":"2019","journal-title":"Immunology"},{"key":"2024091018592818700_CIT0079","doi-asserted-by":"crossref","first-page":"25151355231186005","DOI":"10.1177\/25151355231186005","article-title":"Significant improvement of systemic lupus erythematosus manifestation in children after autologous dendritic cell transfer: a case report and review of literature","volume":"11","author":"Jonny","year":"2023","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"1","key":"2024091018592818700_CIT0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2024091018592818700_CIT0081","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2337\/dc11-0472","article-title":"Phase I (Safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"issue":"17","key":"2024091018592818700_CIT0082","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial","volume":"116","author":"Zubizarreta","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2024091018592818700_CIT0083","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/ecco-jcc\/jjv144","article-title":"Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohn\u2019s disease: a phase I study","volume":"9","author":"Jauregui-Amezaga","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"10","key":"2024091018592818700_CIT0084","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1002\/eji.200838342","article-title":"Altered dendritic cells with tolerizing phenotype in patients with systemic lupus erythematosus","volume":"38","author":"Berkun","year":"2008","journal-title":"Eur J Immunol"},{"issue":"10","key":"2024091018592818700_CIT0085","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/cells8101291","article-title":"Current paradigms of tolerogenic dendritic cells and clinical implications for systemic lupus erythematosus","volume":"8","author":"Ritprajak","year":"2019","journal-title":"Cells"},{"issue":"7534","key":"2024091018592818700_CIT0086","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nature14189","article-title":"The biology of innate lymphoid cells","volume":"517","author":"Artis","year":"2015","journal-title":"Nature"},{"issue":"4","key":"2024091018592818700_CIT0087","first-page":"676","article-title":"Innate lymphoid cells are increased in systemic lupus erythematosus","volume":"37","author":"Hou","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2024091018592818700_CIT0088","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clim.2019.03.008","article-title":"Innate lymphoid cell disturbance with increase in ILC1 in systemic lupus erythematosus","volume":"202","author":"Guo","year":"2019","journal-title":"Clin Immunol"},{"key":"2024091018592818700_CIT0089","doi-asserted-by":"crossref","first-page":"789788","DOI":"10.3389\/fimmu.2021.789788","article-title":"Innate lymphoid cells in autoimmune diseases","volume":"12","author":"Clottu","year":"2022","journal-title":"Front Immunol"},{"key":"2024091018592818700_CIT0090","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3389\/fimmu.2019.00772","article-title":"Innate immune cells\u2019 contribution to systemic lupus erythematosus","volume":"10","author":"Herrada","year":"2019","journal-title":"Front Immunol"},{"issue":"11","key":"2024091018592818700_CIT0091","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/intimm\/dxz036","article-title":"Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis","volume":"31","author":"Hirose","year":"2019","journal-title":"Int Immunol"},{"issue":"5","key":"2024091018592818700_CIT0092","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00005-010-0093-y","article-title":"Monocyte and macrophage abnormalities in systemic lupus erythematosus","volume":"58","author":"Li","year":"2010","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"2024091018592818700_CIT0093","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.clim.2016.08.019","article-title":"CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus","volume":"185","author":"Chalmers","year":"2017","journal-title":"Clin Immunol"},{"issue":"5","key":"2024091018592818700_CIT0094","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00296-005-0031-1","article-title":"Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus","volume":"26","author":"Soerensen","year":"2006","journal-title":"Rheumatol Int"},{"key":"2024091018592818700_CIT0095","doi-asserted-by":"crossref","first-page":"103085","DOI":"10.1016\/j.jaut.2023.103085","article-title":"Functional evaluation of rare OASL variants by analysis of SLE patient-derived iPSCs","volume":"139","author":"Natsumoto","year":"2023","journal-title":"J Autoimmun"},{"issue":"5","key":"2024091018592818700_CIT0096","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/scd.2020.0194","article-title":"Generation of systemic lupus erythematosus patient-derived induced pluripotent stem cells from blood","volume":"30","author":"Li","year":"2021","journal-title":"Stem Cells Dev"},{"issue":"5","key":"2024091018592818700_CIT0097","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1038\/emm.2016.27","article-title":"Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease","volume":"48","author":"Son","year":"2016","journal-title":"Exp Mol Med"},{"key":"2024091018592818700_CIT0098","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1146\/annurev-med-070119-115617","article-title":"Hematopoietic stem cell transplantation for autoimmune disease","volume":"72","author":"Alexander","year":"2021","journal-title":"Annu Rev Med"},{"issue":"10","key":"2024091018592818700_CIT0099","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2024091018592818700_CIT0100","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/sctm.17-0002","article-title":"Serum IFN-\u03b3 predicts the therapeutic effect of mesenchymal stem cells transplantation in systemic lupus erythematosus patients","volume":"6","author":"Wang","year":"2017","journal-title":"Stem Cells Transl. Med"},{"issue":"6","key":"2024091018592818700_CIT0101","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","article-title":"Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR","volume":"17","author":"Zhang","year":"2021","journal-title":"Stem Cell Rev Rep"},{"issue":"12","key":"2024091018592818700_CIT0102","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3727\/096368911X582769c","article-title":"Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience","volume":"22","author":"Wang","year":"2013","journal-title":"Cell Transplant"},{"issue":"2","key":"2024091018592818700_CIT0103","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar4520","article-title":"Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study","volume":"16","author":"Wang","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"2024091018592818700_CIT0104","doi-asserted-by":"crossref","first-page":"185.1","DOI":"10.1136\/annrheumdis-2022-eular.1120","article-title":"Op0279 car-T cell treatment of refractory systemic lupus erythematosus- safety and preliminary efficacy data from the first four patients","volume":"81","author":"Schett","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024091018592818700_CIT0105","doi-asserted-by":"crossref","first-page":"273291","DOI":"10.1155\/2012\/273291","article-title":"Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus","volume":"2012","author":"Wang","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"2024091018592818700_CIT0106","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.stemcr.2018.01.029","article-title":"A long-term follow-up study of allogeneic mesenchymal stem\/stromal cell transplantation in patients with drug-resistant systemic lupus erythematosus","volume":"10","author":"Wang","year":"2018","journal-title":"Stem Cell Rep"},{"issue":"8","key":"2024091018592818700_CIT0107","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","article-title":"A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis","volume":"76","author":"Deng","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/13\/9\/859\/59076559\/szae044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/13\/9\/859\/59076559\/szae044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T19:06:42Z","timestamp":1725995202000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/13\/9\/859\/7699415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":107,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,6,26]]},"published-print":{"date-parts":[[2024,9,10]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szae044","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,6,26]]}}}